ProinPharma Biomed
Proinpharma is committed to providing health solutions worldwide through innovative biotechnological developments. Funded by Argentine scientists, technicians, and investors, the company specializes in RNA and DNA technologies, vaccines, and inhaled protein delivery systems, with a focus on ethics and quality in GMP-certified facilities.
Industries
Nr. of Employees
medium (51-250)
ProinPharma Biomed
Products
Nebulized inhaled interferon beta therapeutic candidate
A nebulized interferon beta therapeutic candidate that is described as being in an exploratory clinical phase.
DNA/RNA-based vaccine candidates
Vaccine candidates developed using DNA and RNA technologies.
Inhaled protein delivery platform candidates
Platform technologies for delivering therapeutic proteins via inhalation, intended to support multiple inhaled product candidates.
Nebulized inhaled interferon beta therapeutic candidate
A nebulized interferon beta therapeutic candidate that is described as being in an exploratory clinical phase.
DNA/RNA-based vaccine candidates
Vaccine candidates developed using DNA and RNA technologies.
Inhaled protein delivery platform candidates
Platform technologies for delivering therapeutic proteins via inhalation, intended to support multiple inhaled product candidates.
Services
On-site manufacturing of biotechnology products in GMP-compliant facilities for vaccine and therapeutic candidates.
Research and development services for DNA- and RNA-based vaccine candidates and development of inhaled protein delivery systems.
Analytical testing and diagnostic services including blood bank and chemistry panels, hematology, histology, coagulation, cytology, pathology testing and mineral assays for development and QC.
Support for early clinical development activities for inhaled therapeutics, demonstrated by an exploratory-phase nebulized interferon beta program.
On-site manufacturing of biotechnology products in GMP-compliant facilities for vaccine and therapeutic candidates.
Research and development services for DNA- and RNA-based vaccine candidates and development of inhaled protein delivery systems.
Analytical testing and diagnostic services including blood bank and chemistry panels, hematology, histology, coagulation, cytology, pathology testing and mineral assays for development and QC.
Support for early clinical development activities for inhaled therapeutics, demonstrated by an exploratory-phase nebulized interferon beta program.
Expertise Areas
- RNA therapeutics and vaccine development
- Inhaled protein delivery systems and nebulized therapeutics
- GMP biologics manufacturing
- Clinical development of early-phase biologics
Key Technologies
- DNA and RNA technologies
- Nebulization and inhaled delivery
- GMP manufacturing systems
- Clinical trial operations (early-phase)